PATENT CLAIM ANALYSIS

Application Number: 15746966
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-11
Patent Classification: ["544", "331000"]

Abstract:
Provided is an EGFR inhibitor and a pharmaceutically acceptable salt and a polymorph thereof, and a use thereof. In particular, provided is a polymorph, a pharmaceutically acceptable salt or a prodrug of N-(2-(4-(dimethylamino)piperid-1-yl)-5-(5-fluoro-4-(1-methyl-1H-pyrazol-4-yl) pyrimidin-2-ylamino)-4-methoxy phenyl) acrylamide. In addition, also provided is a pharmaceutical composition containing the inhibitor and a use thereof.

Claim (Index 5):
The compound of  claim 3 , or a pharmaceutically acceptable salt, or a prodrug thereof, wherein the crystal is selected from the group consisting of:\n A crystalline form of the hydrochloride of compound of formula X, i.e. crystal form A, which has an X-ray powder diffraction pattern with diffraction angle 2\u03b8(\u00b0) values of the following group A1: 8.47\u00b10.10, 20.32\u00b10.10, 23.31\u00b10.10 (the highest peak) and 25.98\u00b10.10; B crystalline form of the phosphate of compound of formula X, i.e. crystal form B, which has an X-ray powder diffraction pattern with diffraction angle 2\u03b8(\u00b0) values of the following group B1: 11.94\u00b10.10, 19.92\u00b10.10 (the highest peak), 22.27\u00b10.10, 23.93\u00b10.10; C-1 crystalline form of the maleate of compound of formula X, i.e. crystal form C-1, which has an X-ray powder diffraction pattern with diffraction angle 2\u03b8(\u00b0) values of the following group C-1-1: 8.73\u00b10.10, 13.37\u00b10.10, 18.08\u00b10.10 and 25.55\u00b10.10 (the highest peak); C-2 crystalline form of the maleate of compound of formula X, i.e. crystal form C-2, which has an X-ray powder diffraction pattern with diffraction angle 2\u03b8(\u00b0) values of the following group C-2-1:7.48\u00b10.10 (the highest peak), 8.60\u00b10.10, 20.63\u00b10.10 and 23.27\u00b10.10; D crystalline form of the L-malate of compound of formula X, i.e. crystal form D, which has an X-ray powder diffraction pattern with diffraction angle 2\u03b8(\u00b0) values of the following group D1:7.47\u00b10.10, 18.75\u00b10.10, 22.69\u00b10.10 (the highest peak) and 24.39\u00b10.10; and E crystalline form of the adipate of compound of formula X, i.e. crystal form E, which has an X-ray powder diffraction pattern with diffraction angle 2\u03b8(\u00b0) values of the following group E1:7.43\u00b10.10, 18.45\u00b10.10, 21.64\u00b10.10 (the highest peak) and 24.22\u00b10.10.

Metadata:
- Claim Count in Document: 10.0
- Percentile: 86.0
- Lexical Diversity: 1.85366
- Patent Class: 544.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['16098103', '13019262', '15753993', '14631712', '15571582']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7823446207553665
- 35 USC 102 Novelty (BERT): 0.5512147035179286
- Combined Prediction Score: 0.7592316290316227
- Mean Citation Score: 313.714576
- Max Citation Score: 425.19266
- Similarity Product: 301.83870293755297

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test